{"id":59558,"date":"2026-03-16T13:48:32","date_gmt":"2026-03-16T05:48:32","guid":{"rendered":"https:\/\/flcube.com\/?p=59558"},"modified":"2026-03-16T13:48:32","modified_gmt":"2026-03-16T05:48:32","slug":"biogens-salanersen-shows-75-nfl-reduction-in-sma-phase-ib-once-yearly-aso-advances-to-phase-iii","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59558","title":{"rendered":"Biogen&#8217;s Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III"},"content":{"rendered":"\n<p><strong>Biogen Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>) presented <strong>supplemental Phase Ib data<\/strong> for <strong>salanersen<\/strong>, its <strong>investigational antisense oligonucleotide (ASO)<\/strong> for <strong>spinal muscular atrophy (SMA)<\/strong>, at the <strong>2026 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference<\/strong>. The <strong>once-yearly administered<\/strong> therapy demonstrated <strong>substantial neurofilament light chain (NfL) reductions up to 75%<\/strong> at 6 months in participants with elevated baseline levels, with <strong>all 24 treated patients showing improvements<\/strong> in endpoint measures and <strong>50% achieving new WHO motor milestones<\/strong>. The <strong>80 mg dose<\/strong> is now being <strong>evaluated in Phase III<\/strong>, positioning salanersen as a <strong>potential best-in-class SMA treatment<\/strong> with <strong>dramatically reduced dosing burden<\/strong> versus existing therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-data-summary\">Clinical Data Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Salanersen (40 mg \/ 80 mg)<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>NfL Reduction<\/strong><\/td><td>Up to 75% at 6 months<\/td><td><strong>Substantial neuronal degeneration marker improvement<\/strong><\/td><\/tr><tr><td><strong>NfL Maintenance<\/strong><\/td><td>Sustained throughout follow-up<\/td><td>Durable treatment effect<\/td><\/tr><tr><td><strong>Motor Milestones<\/strong><\/td><td>12\/24 (50%) achieved \u22651 new WHO motor milestone<\/td><td><strong>Functional improvement<\/strong><\/td><\/tr><tr><td><strong>Motor Preservation<\/strong><\/td><td>24\/24 (100%) maintained baseline motor abilities<\/td><td>No disease progression<\/td><\/tr><tr><td><strong>Overall Improvement<\/strong><\/td><td>24\/24 (100%) showed improvement in \u22651 endpoint<\/td><td>Universal treatment benefit<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Generally well-tolerated; mostly mild-moderate AEs<\/td><td>Favorable tolerability profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Study Population:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>N=24<\/strong> participants aged 0.5-12 years<\/li>\n\n\n\n<li><strong>Prior Treatment:<\/strong> All received \u22652 doses of salanersen (40 mg or 80 mg)<\/li>\n\n\n\n<li><strong>Biomarker Focus:<\/strong> NfL (neurofilament light chain) \u2013 marker of axonal injury\/neurodegeneration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-differentiation\">Drug Profile &amp; Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Salanersen Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Class<\/strong><\/td><td>Antisense oligonucleotide (ASO)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>SMN2 splicing modifier (increases functional SMN protein)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Promotes exon 7 inclusion in SMN2 mRNA \u2192 increased survival motor neuron (SMN) protein production<\/td><\/tr><tr><td><strong>Dosing Frequency<\/strong><\/td><td><strong>Once-yearly<\/strong> (vs. quarterly for Spinraza, daily for Evrysdi)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Intrathecal injection<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase Ib (completed); Phase III (ongoing with 80 mg dose)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Competitive Positioning vs. Standard of Care:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Developer<\/th><th>Mechanism<\/th><th>Dosing<\/th><th>Salanersen Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Spinraza (nusinersen)<\/strong><\/td><td>Biogen<\/td><td>SMN2 ASO<\/td><td>Every 4 months (intrathecal)<\/td><td><strong>Once-yearly frequency<\/strong><\/td><\/tr><tr><td><strong>Evrysdi (risdiplam)<\/strong><\/td><td>Roche<\/td><td>SMN2 splicing modifier<\/td><td>Daily oral<\/td><td>Reduced treatment burden; intrathecal delivery to CNS<\/td><\/tr><tr><td><strong>Zolgensma<\/strong><\/td><td>Novartis<\/td><td>SMN1 gene therapy<\/td><td>One-time IV<\/td><td>Salanersen for older patients; retreatment possible<\/td><\/tr><tr><td><strong>Biogen<\/strong><\/td><td><strong>Salanersen<\/strong><\/td><td><strong>Next-gen SMN2 ASO<\/strong><\/td><td><strong>Once-yearly<\/strong><\/td><td><strong>Superior convenience; 75% NfL reduction; Phase III advancement<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-impact\">Strategic Context &amp; Market Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>SMA Market Evolution<\/strong><\/td><td>Transition from acute treatment to long-term management; dosing convenience increasingly valued<\/td><\/tr><tr><td><strong>Biogen Franchise Defense<\/strong><\/td><td>Salanersen protects Biogen&#8217;s SMA leadership against Spinraza LOE (loss of exclusivity 2028+)<\/td><\/tr><tr><td><strong>NfL as Biomarker<\/strong><\/td><td>75% reduction validates target engagement; potential surrogate endpoint for accelerated approval<\/td><\/tr><tr><td><strong>Pediatric Expansion<\/strong><\/td><td>0.5-12 year data supports broad age indication; pre-symptomatic treatment potential<\/td><\/tr><tr><td><strong>Phase III Timing<\/strong><\/td><td>80 mg dose selection based on Phase Ib efficacy\/safety; registrational data anticipated 2027-2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase Ib<\/strong><\/td><td>Complete<\/td><td>Dose-ranging (40 mg, 80 mg); NfL biomarker validation; safety profile<\/td><\/tr><tr><td><strong>Phase III<\/strong><\/td><td>Ongoing (2025-2028)<\/td><td>80 mg dose efficacy vs. standard of care; motor function endpoints; long-term safety<\/td><\/tr><tr><td><strong>Regulatory Filing<\/strong><\/td><td>2028-2029<\/td><td>U.S., EU, Japan NDAs; breakthrough therapy designation potential<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>2029-2030<\/td><td>Spinraza replacement strategy; premium pricing for convenience advantage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase III outcomes, NfL biomarker validation, and competitive positioning for salanersen in spinal muscular atrophy. Actual results may differ due to long-term safety monitoring, competitive dynamics with gene therapy, and pricing negotiations for convenience premium.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biogen Inc. (NASDAQ: BIIB) presented supplemental Phase Ib data for salanersen, its investigational antisense oligonucleotide&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59559,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,17,993,64],"class_list":["post-59558","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biogen","tag-clinical-trial-results","tag-nasdaq-biib","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biogen&#039;s Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biogen Inc. (NASDAQ: BIIB) presented supplemental Phase Ib data for salanersen, its investigational antisense oligonucleotide (ASO) for spinal muscular atrophy (SMA), at the 2026 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference. The once-yearly administered therapy demonstrated substantial neurofilament light chain (NfL) reductions up to 75% at 6 months in participants with elevated baseline levels, with all 24 treated patients showing improvements in endpoint measures and 50% achieving new WHO motor milestones. The 80 mg dose is now being evaluated in Phase III, positioning salanersen as a potential best-in-class SMA treatment with dramatically reduced dosing burden versus existing therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59558\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen&#039;s Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III\" \/>\n<meta property=\"og:description\" content=\"Biogen Inc. (NASDAQ: BIIB) presented supplemental Phase Ib data for salanersen, its investigational antisense oligonucleotide (ASO) for spinal muscular atrophy (SMA), at the 2026 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference. The once-yearly administered therapy demonstrated substantial neurofilament light chain (NfL) reductions up to 75% at 6 months in participants with elevated baseline levels, with all 24 treated patients showing improvements in endpoint measures and 50% achieving new WHO motor milestones. The 80 mg dose is now being evaluated in Phase III, positioning salanersen as a potential best-in-class SMA treatment with dramatically reduced dosing burden versus existing therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59558\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T05:48:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59558#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59558\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen&#8217;s Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III\",\"datePublished\":\"2026-03-16T05:48:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59558\"},\"wordCount\":502,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59558#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1601.webp\",\"keywords\":[\"Biogen\",\"Clinical trial results\",\"NASDAQ: BIIB\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59558#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59558\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59558\",\"name\":\"Biogen's Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59558#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59558#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1601.webp\",\"datePublished\":\"2026-03-16T05:48:32+00:00\",\"description\":\"Biogen Inc. (NASDAQ: BIIB) presented supplemental Phase Ib data for salanersen, its investigational antisense oligonucleotide (ASO) for spinal muscular atrophy (SMA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The once-yearly administered therapy demonstrated substantial neurofilament light chain (NfL) reductions up to 75% at 6 months in participants with elevated baseline levels, with all 24 treated patients showing improvements in endpoint measures and 50% achieving new WHO motor milestones. The 80 mg dose is now being evaluated in Phase III, positioning salanersen as a potential best-in-class SMA treatment with dramatically reduced dosing burden versus existing therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59558#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59558\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59558#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1601.webp\",\"width\":1080,\"height\":608,\"caption\":\"Biogen's Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59558#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen&#8217;s Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen's Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III - Insight, China&#039;s Pharmaceutical Industry","description":"Biogen Inc. (NASDAQ: BIIB) presented supplemental Phase Ib data for salanersen, its investigational antisense oligonucleotide (ASO) for spinal muscular atrophy (SMA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The once-yearly administered therapy demonstrated substantial neurofilament light chain (NfL) reductions up to 75% at 6 months in participants with elevated baseline levels, with all 24 treated patients showing improvements in endpoint measures and 50% achieving new WHO motor milestones. The 80 mg dose is now being evaluated in Phase III, positioning salanersen as a potential best-in-class SMA treatment with dramatically reduced dosing burden versus existing therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59558","og_locale":"en_US","og_type":"article","og_title":"Biogen's Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III","og_description":"Biogen Inc. (NASDAQ: BIIB) presented supplemental Phase Ib data for salanersen, its investigational antisense oligonucleotide (ASO) for spinal muscular atrophy (SMA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The once-yearly administered therapy demonstrated substantial neurofilament light chain (NfL) reductions up to 75% at 6 months in participants with elevated baseline levels, with all 24 treated patients showing improvements in endpoint measures and 50% achieving new WHO motor milestones. The 80 mg dose is now being evaluated in Phase III, positioning salanersen as a potential best-in-class SMA treatment with dramatically reduced dosing burden versus existing therapies.","og_url":"https:\/\/flcube.com\/?p=59558","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-16T05:48:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59558#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59558"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen&#8217;s Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III","datePublished":"2026-03-16T05:48:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59558"},"wordCount":502,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59558#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1601.webp","keywords":["Biogen","Clinical trial results","NASDAQ: BIIB","RNAi \/ ASO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59558#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59558","url":"https:\/\/flcube.com\/?p=59558","name":"Biogen's Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59558#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59558#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1601.webp","datePublished":"2026-03-16T05:48:32+00:00","description":"Biogen Inc. (NASDAQ: BIIB) presented supplemental Phase Ib data for salanersen, its investigational antisense oligonucleotide (ASO) for spinal muscular atrophy (SMA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The once-yearly administered therapy demonstrated substantial neurofilament light chain (NfL) reductions up to 75% at 6 months in participants with elevated baseline levels, with all 24 treated patients showing improvements in endpoint measures and 50% achieving new WHO motor milestones. The 80 mg dose is now being evaluated in Phase III, positioning salanersen as a potential best-in-class SMA treatment with dramatically reduced dosing burden versus existing therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59558#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59558"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59558#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1601.webp","width":1080,"height":608,"caption":"Biogen's Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59558#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen&#8217;s Salanersen Shows 75% NfL Reduction in SMA Phase Ib \u2013 Once-Yearly ASO Advances to Phase III"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59558"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59558\/revisions"}],"predecessor-version":[{"id":59560,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59558\/revisions\/59560"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59559"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}